# Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients

> **NCT06574984** · — · RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 900 (estimated)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia A

## Interventions

- **DRUG:** Turoctocog alfa

## Key facts

- **NCT ID:** NCT06574984
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-10
- **Primary completion:** 2026-02-27
- **Final completion:** 2026-04-30
- **Target enrollment:** 900 (ESTIMATED)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06574984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06574984, "Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06574984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*